Browse RGCC

Summary
SymbolRGCC
Nameregulator of cell cycle
Aliases bA157L14.2; RGC-32; RGC32; response gene to complement 32; C13orf15; chromosome 13 open reading frame 15; re ......
Chromosomal Location13q14.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm. Nucleus. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Note=Cytoplasmic in unstimulated cells. Nuclear after activation by complement. Associated with the centrosome during prometaphase and metaphase.
Domain PF15151 Response gene to complement 32 protein family
Function

Modulates the activity of cell cycle-specific kinases. Enhances CDK1 activity. May contribute to the regulation of the cell cycle. May inhibit growth of glioma cells by promoting arrest of mitotic progression at the G2/M transition. Fibrogenic factor contributing to the pathogenesis of renal fibrosis through fibroblast activation.

> Gene Ontology
 
Biological Process GO:0000075 cell cycle checkpoint
GO:0000077 DNA damage checkpoint
GO:0000079 regulation of cyclin-dependent protein serine/threonine kinase activity
GO:0000082 G1/S transition of mitotic cell cycle
GO:0001100 negative regulation of exit from mitosis
GO:0001525 angiogenesis
GO:0001666 response to hypoxia
GO:0001667 ameboidal-type cell migration
GO:0001818 negative regulation of cytokine production
GO:0001819 positive regulation of cytokine production
GO:0001837 epithelial to mesenchymal transition
GO:0001935 endothelial cell proliferation
GO:0001936 regulation of endothelial cell proliferation
GO:0001937 negative regulation of endothelial cell proliferation
GO:0003330 regulation of extracellular matrix constituent secretion
GO:0003331 positive regulation of extracellular matrix constituent secretion
GO:0006956 complement activation
GO:0006959 humoral immune response
GO:0006977 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest
GO:0007015 actin filament organization
GO:0007050 cell cycle arrest
GO:0007067 mitotic nuclear division
GO:0007088 regulation of mitotic nuclear division
GO:0007093 mitotic cell cycle checkpoint
GO:0007096 regulation of exit from mitosis
GO:0007162 negative regulation of cell adhesion
GO:0007346 regulation of mitotic cell cycle
GO:0009306 protein secretion
GO:0010458 exit from mitosis
GO:0010594 regulation of endothelial cell migration
GO:0010596 negative regulation of endothelial cell migration
GO:0010631 epithelial cell migration
GO:0010632 regulation of epithelial cell migration
GO:0010633 negative regulation of epithelial cell migration
GO:0010639 negative regulation of organelle organization
GO:0010712 regulation of collagen metabolic process
GO:0010714 positive regulation of collagen metabolic process
GO:0010717 regulation of epithelial to mesenchymal transition
GO:0010718 positive regulation of epithelial to mesenchymal transition
GO:0010948 negative regulation of cell cycle process
GO:0016525 negative regulation of angiogenesis
GO:0022407 regulation of cell-cell adhesion
GO:0022408 negative regulation of cell-cell adhesion
GO:0030038 contractile actin filament bundle assembly
GO:0030198 extracellular matrix organization
GO:0030330 DNA damage response, signal transduction by p53 class mediator
GO:0030336 negative regulation of cell migration
GO:0031032 actomyosin structure organization
GO:0031570 DNA integrity checkpoint
GO:0031571 mitotic G1 DNA damage checkpoint
GO:0031657 regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle
GO:0031659 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle
GO:0032147 activation of protein kinase activity
GO:0032231 regulation of actin filament bundle assembly
GO:0032233 positive regulation of actin filament bundle assembly
GO:0032956 regulation of actin cytoskeleton organization
GO:0032963 collagen metabolic process
GO:0032964 collagen biosynthetic process
GO:0032965 regulation of collagen biosynthetic process
GO:0032967 positive regulation of collagen biosynthetic process
GO:0032970 regulation of actin filament-based process
GO:0033674 positive regulation of kinase activity
GO:0036293 response to decreased oxygen levels
GO:0036294 cellular response to decreased oxygen levels
GO:0040013 negative regulation of locomotion
GO:0042770 signal transduction in response to DNA damage
GO:0043062 extracellular structure organization
GO:0043149 stress fiber assembly
GO:0043534 blood vessel endothelial cell migration
GO:0043535 regulation of blood vessel endothelial cell migration
GO:0043537 negative regulation of blood vessel endothelial cell migration
GO:0043542 endothelial cell migration
GO:0044089 positive regulation of cellular component biogenesis
GO:0044236 multicellular organism metabolic process
GO:0044246 regulation of multicellular organismal metabolic process
GO:0044253 positive regulation of multicellular organismal metabolic process
GO:0044259 multicellular organismal macromolecule metabolic process
GO:0044331 cell-cell adhesion mediated by cadherin
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044773 mitotic DNA damage checkpoint
GO:0044774 mitotic DNA integrity checkpoint
GO:0044783 G1 DNA damage checkpoint
GO:0044819 mitotic G1/S transition checkpoint
GO:0044843 cell cycle G1/S phase transition
GO:0045737 positive regulation of cyclin-dependent protein serine/threonine kinase activity
GO:0045765 regulation of angiogenesis
GO:0045786 negative regulation of cell cycle
GO:0045787 positive regulation of cell cycle
GO:0045839 negative regulation of mitotic nuclear division
GO:0045840 positive regulation of mitotic nuclear division
GO:0045860 positive regulation of protein kinase activity
GO:0045930 negative regulation of mitotic cell cycle
GO:0045931 positive regulation of mitotic cell cycle
GO:0048514 blood vessel morphogenesis
GO:0048762 mesenchymal cell differentiation
GO:0050663 cytokine secretion
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050680 negative regulation of epithelial cell proliferation
GO:0050707 regulation of cytokine secretion
GO:0050708 regulation of protein secretion
GO:0050709 negative regulation of protein secretion
GO:0050710 negative regulation of cytokine secretion
GO:0050714 positive regulation of protein secretion
GO:0050715 positive regulation of cytokine secretion
GO:0051017 actin filament bundle assembly
GO:0051047 positive regulation of secretion
GO:0051048 negative regulation of secretion
GO:0051051 negative regulation of transport
GO:0051052 regulation of DNA metabolic process
GO:0051054 positive regulation of DNA metabolic process
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051222 positive regulation of protein transport
GO:0051224 negative regulation of protein transport
GO:0051271 negative regulation of cellular component movement
GO:0051492 regulation of stress fiber assembly
GO:0051493 regulation of cytoskeleton organization
GO:0051495 positive regulation of cytoskeleton organization
GO:0051496 positive regulation of stress fiber assembly
GO:0051783 regulation of nuclear division
GO:0051784 negative regulation of nuclear division
GO:0051785 positive regulation of nuclear division
GO:0060485 mesenchyme development
GO:0061572 actin filament bundle organization
GO:0070278 extracellular matrix constituent secretion
GO:0070482 response to oxygen levels
GO:0071156 regulation of cell cycle arrest
GO:0071158 positive regulation of cell cycle arrest
GO:0071453 cellular response to oxygen levels
GO:0071456 cellular response to hypoxia
GO:0071850 mitotic cell cycle arrest
GO:0071897 DNA biosynthetic process
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0072331 signal transduction by p53 class mediator
GO:0072376 protein activation cascade
GO:0072395 signal transduction involved in cell cycle checkpoint
GO:0072401 signal transduction involved in DNA integrity checkpoint
GO:0072413 signal transduction involved in mitotic cell cycle checkpoint
GO:0072422 signal transduction involved in DNA damage checkpoint
GO:0072431 signal transduction involved in mitotic G1 DNA damage checkpoint
GO:0072537 fibroblast activation
GO:0072577 endothelial cell apoptotic process
GO:0085029 extracellular matrix assembly
GO:0090068 positive regulation of cell cycle process
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0090269 fibroblast growth factor production
GO:0090270 regulation of fibroblast growth factor production
GO:0090272 negative regulation of fibroblast growth factor production
GO:1901201 regulation of extracellular matrix assembly
GO:1901203 positive regulation of extracellular matrix assembly
GO:1901342 regulation of vasculature development
GO:1901343 negative regulation of vasculature development
GO:1901987 regulation of cell cycle phase transition
GO:1901988 negative regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1901991 negative regulation of mitotic cell cycle phase transition
GO:1902400 intracellular signal transduction involved in G1 DNA damage checkpoint
GO:1902402 signal transduction involved in mitotic DNA damage checkpoint
GO:1902403 signal transduction involved in mitotic DNA integrity checkpoint
GO:1902806 regulation of cell cycle G1/S phase transition
GO:1902807 negative regulation of cell cycle G1/S phase transition
GO:1903053 regulation of extracellular matrix organization
GO:1903055 positive regulation of extracellular matrix organization
GO:1903531 negative regulation of secretion by cell
GO:1903532 positive regulation of secretion by cell
GO:1904019 epithelial cell apoptotic process
GO:1904029 regulation of cyclin-dependent protein kinase activity
GO:1904031 positive regulation of cyclin-dependent protein kinase activity
GO:1904035 regulation of epithelial cell apoptotic process
GO:1904037 positive regulation of epithelial cell apoptotic process
GO:1904950 negative regulation of establishment of protein localization
GO:1904951 positive regulation of establishment of protein localization
GO:2000045 regulation of G1/S transition of mitotic cell cycle
GO:2000047 regulation of cell-cell adhesion mediated by cadherin
GO:2000048 negative regulation of cell-cell adhesion mediated by cadherin
GO:2000134 negative regulation of G1/S transition of mitotic cell cycle
GO:2000146 negative regulation of cell motility
GO:2000181 negative regulation of blood vessel morphogenesis
GO:2000278 regulation of DNA biosynthetic process
GO:2000351 regulation of endothelial cell apoptotic process
GO:2000353 positive regulation of endothelial cell apoptotic process
GO:2000573 positive regulation of DNA biosynthetic process
Molecular Function GO:0008047 enzyme activator activity
GO:0019207 kinase regulator activity
GO:0019209 kinase activator activity
GO:0019887 protein kinase regulator activity
GO:0030295 protein kinase activator activity
GO:0046332 SMAD binding
GO:0070412 R-SMAD binding
Cellular Component GO:0005813 centrosome
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-6791312: TP53 Regulates Transcription of Cell Cycle Genes
R-HSA-6804115: TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
R-HSA-3700989: Transcriptional Regulation by TP53
Summary
SymbolRGCC
Nameregulator of cell cycle
Aliases bA157L14.2; RGC-32; RGC32; response gene to complement 32; C13orf15; chromosome 13 open reading frame 15; re ......
Chromosomal Location13q14.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RGCC and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolRGCC
Nameregulator of cell cycle
Aliases bA157L14.2; RGC-32; RGC32; response gene to complement 32; C13orf15; chromosome 13 open reading frame 15; re ......
Chromosomal Location13q14.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RGCC in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolRGCC
Nameregulator of cell cycle
Aliases bA157L14.2; RGC-32; RGC32; response gene to complement 32; C13orf15; chromosome 13 open reading frame 15; re ......
Chromosomal Location13q14.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RGCC in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.7410.0312
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.9920.553
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5630.671
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5020.291
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.0130.466
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.150.936
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.3740.319
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0290.98
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.6920.56
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.0340.554
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.5940.546
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2380.0617
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RGCC in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.407.40.0709
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRGCC
Nameregulator of cell cycle
Aliases bA157L14.2; RGC-32; RGC32; response gene to complement 32; C13orf15; chromosome 13 open reading frame 15; re ......
Chromosomal Location13q14.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RGCC. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRGCC
Nameregulator of cell cycle
Aliases bA157L14.2; RGC-32; RGC32; response gene to complement 32; C13orf15; chromosome 13 open reading frame 15; re ......
Chromosomal Location13q14.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RGCC. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RGCC.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRGCC
Nameregulator of cell cycle
Aliases bA157L14.2; RGC-32; RGC32; response gene to complement 32; C13orf15; chromosome 13 open reading frame 15; re ......
Chromosomal Location13q14.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RGCC. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRGCC
Nameregulator of cell cycle
Aliases bA157L14.2; RGC-32; RGC32; response gene to complement 32; C13orf15; chromosome 13 open reading frame 15; re ......
Chromosomal Location13q14.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RGCC expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRGCC
Nameregulator of cell cycle
Aliases bA157L14.2; RGC-32; RGC32; response gene to complement 32; C13orf15; chromosome 13 open reading frame 15; re ......
Chromosomal Location13q14.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RGCC and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRGCC
Nameregulator of cell cycle
Aliases bA157L14.2; RGC-32; RGC32; response gene to complement 32; C13orf15; chromosome 13 open reading frame 15; re ......
Chromosomal Location13q14.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RGCC collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.